Drug Trial Radar · NCT06462417
Efficacy and Safety of Arbidol in the Treatment of Allergic Rhinitis
Last checked: Nov 20, 2026Latest source record: May 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
15
Planned (sponsor's estimate)
Start
Jul 11, 2024
Primary completion
Jun 30, 2025
Study completion Jun 30, 2025
Sponsor
- Lead sponsor
- Zheng LiuAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Natural Science Foundation of China
- First posted
- Jun 17, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The most important treatment for AR is topical nasal medications (including nasal corticosteroids, nasal antihistamines, nasal decongestants, and nasal saline irrigation etc.), which are still limited. Arbidol may inhibit molecular targets involved in the pathogenesis of AR. This study intends to explore the effect of Arbidol in the treatment of allergic rhinitis and evaluate its efficacy and safety.
Conditions
- Allergic Rhinitis
Interventions
ArbidolDrug
Arbidol Hydrochloride Tablets 0.2g/d for 2 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- The protein level of molecular biomarkers in nasal epithelial cellsTime frame: 14 days
- The mRNA level of inflammation molecular biomarkers in nasal epithelial cellsTime frame: 14 days
- The level of inflammation molecular biomarkers in nasal lavage fluidTime frame: 14 days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology
Wuhan, Hubei, China · Recruiting
Department of ENT, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.